Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSB-D121
- Development stage
- Preclinical
- Lead developer
- Greenstone
- Modality
- Small Molecules
01
Overview
GSB-D121 is an investigational small molecule therapeutic being developed by Greenstone Bio for the treatment of fibrosis. The compound was identified using Greenstone's proprietary "Clinical Trial in a Dish" platform, which leverages patient-derived induced pluripotent stem cells (iPSCs) and functional genomics to discover drugs that demonstrate efficacy across diverse human genetic backgrounds. As of 2024, GSB-D121 is in the IND-enabling phase of development. While the specific molecular target has not been publicly disclosed, the program is designed to address fibrotic disease pathways identified through human-centric discovery models.
Beyond the preview
Go deeper on GSB-D121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSB-D121.